WhatsApp

Official WhatsApp

  • Klapanunggal, Bogor. 16820

post-image

The Pharmaceutical Technology Center signed an MOU with an Indonesian regenerative medicine company to assist the Southeast Asian market

Following a partnership with a Singapore company, the Pharmaceutical Industry Technology Development Center (PTC) today (8 August) announced that it has entered into a partnership with PT. Sel Regenerasi Biotek signed a letter of intent to collaborate on the development of cell therapy products for infectious diseases, and the company will soon set up a subsidiary in Taiwan, and in the future, it will bridge with Taiwan's regenerative medicine CDMO manufacturers through the Pharmaceutical Technology Center.  

PT. Sel Regenerasi Biotek, a company focused on biologic cell medical and biotechnology research, has partnered and looking an opportunity with Indonesia's National Center for Infectious Diseases Hospital  to conduct clinical trials of cellular medical and stem cell exosomes for the treatment of post-tuberculosis sequelae.   

According to the Pharmaceutical Technology Center, through the subsidy program of the Department of Industrial Technology of the Ministry of Economic Affairs, it has successfully established a series of regenerative medicine technologies such as cell culture medium formulation optimization platform, precision immunomodulation, and neural repair stem cell process, which has become a basis for attracting international cooperation, and after signing a cooperation agreement with Singapore's ECCO Group, it has once again attracted ASEAN countries to sign a memorandum of cooperation to cooperate in the development of regenerative medicine technology products.   

ASEAN countries are seen as the next fast-growing region, and Indonesia is the largest economy in ASEAN, with a population of 270 million, making it a medical market with huge growth potential. This cooperation project is expected to inject another breath of fresh water into Taiwan's emerging cell therapy industry chain, become a stepping stone to enter the ASEAN market, and open up a new development space for the regenerative medicine field of the two countries and even ASEAN countries. 

In response to the cooperation between the two parties, PT. Bintarna Tardy, chairman of Sel Regenerasi Biotek, said that in the near future, a subsidiary will be set up in Taiwan, and the advanced process of stem cells and exosomes will be introduced in cooperation with the Pharmaceutical Technology Center, and the CDMO energy will be produced with the help of cells in Taiwan to accelerate the process of clinical trials. 

The Pharmaceutical Technology Center noted that it will assist PT. Sel Regenerasi Biotek has set up a subsidiary in Taiwan to prepare pre-clinical (pre-IND) data for cell preparations, and assist in bridging CDMO companies in domestic cell production, expanding international business opportunities for domestic cell manufacturers and opening up new blue ocean markets in Southeast Asia.

Telah dibaca 61 kali